Najam A. Awan

2.9k total citations
77 papers, 2.0k citations indexed

About

Najam A. Awan is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Najam A. Awan has authored 77 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Cardiology and Cardiovascular Medicine, 29 papers in Surgery and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Najam A. Awan's work include Hemodynamic Monitoring and Therapy (26 papers), Heart Failure Treatment and Management (23 papers) and Cardiac electrophysiology and arrhythmias (15 papers). Najam A. Awan is often cited by papers focused on Hemodynamic Monitoring and Therapy (26 papers), Heart Failure Treatment and Management (23 papers) and Cardiac electrophysiology and arrhythmias (15 papers). Najam A. Awan collaborates with scholars based in United States, United Kingdom and United Arab Emirates. Najam A. Awan's co-authors include Dean T. Mason, Richard R. Miller, Kevin S. Maxwell, D. T. Mason, Anthony N. DeMaria, Ezra A. Amsterdam, Kathleen E. Needham, Zakauddin Vera, Aung Ko Win and Alexander Neumann and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Najam A. Awan

72 papers receiving 1.8k citations

Peers

Najam A. Awan
J. N. Cohn United States
F Burkart Switzerland
Fetnat M. Fouad United States
Robert DiBianco United States
A Polese Italy
Peter E. Pool United States
T Vrobel United States
Madeline Yushak United States
G. G. Belz Germany
Najam A. Awan
Citations per year, relative to Najam A. Awan Najam A. Awan (= 1×) peers Peter H.J.M. Dunselman

Countries citing papers authored by Najam A. Awan

Since Specialization
Citations

This map shows the geographic impact of Najam A. Awan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Najam A. Awan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Najam A. Awan more than expected).

Fields of papers citing papers by Najam A. Awan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Najam A. Awan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Najam A. Awan. The network helps show where Najam A. Awan may publish in the future.

Co-authorship network of co-authors of Najam A. Awan

This figure shows the co-authorship network connecting the top 25 collaborators of Najam A. Awan. A scholar is included among the top collaborators of Najam A. Awan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Najam A. Awan. Najam A. Awan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Awan, Najam A., et al.. (2022). Immune Tolerance Induction in a Severe Hemophilia B Child with Low Titer Inhibitors. SHILAP Revista de lepidopterología. 13(4). 285–287.
2.
Vismara, Louis A., Richard R. Miller, Craig M. Pratt, et al.. (2015). Reduction of Coronary Sudden Death by Aortocoronary Bypass Surgery. Advances in cardiology. 147–153.
3.
Tonkon, Melvin J., et al.. (2000). A STUDY OF THE EFFICACY AND SAFETY OF IRBESARTAN IN COMBINATION WITH CONVENTIONAL THERAPY, INCLUDING ACE INHIBITORS, IN HEART FAILURE. International Journal of Clinical Practice. 54(1). 11–18. 43 indexed citations
4.
Tonkon, Melvin J., Najam A. Awan, Imran Khan Niazi, et al.. (1998). Irbesartan combined with conventional therapy, including angiotensin converting enzyme inhibitors, in heart failure. Journal of the American College of Cardiology. 31. 188–188. 8 indexed citations
5.
Awan, Najam A. & Dean T. Mason. (1996). Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. American Heart Journal. 131(1). 177–185. 36 indexed citations
6.
Anders, Robert J., Stanford S. Jhee, John J. Sramek, et al.. (1995). Placebo-controlled evaluation of three doses of a controlled-onset, extended-release formulation of verapamil in the treatment of stable angina pectoris. The American Journal of Cardiology. 75(16). 1102–1106. 35 indexed citations
7.
Ezekowitz, Michael D., Kenneth F. Hossack, Jawahar L. Mehta, et al.. (1995). Amlodipine in chronic stable angina: Results of a multicenter double-blind crossover trial. American Heart Journal. 129(3). 527–535. 35 indexed citations
8.
DiBianco, Robert, Jang Bahadur Singh, Najam A. Awan, et al.. (1992). Amlodipine combined with beta blockade for chronic angina: Results of a multicenter, placebo‐controlled, randomized double‐blind study. Clinical Cardiology. 15(7). 519–524. 18 indexed citations
9.
Thadani, Udho, Najam A. Awan, George Kubac, Sigmund Silber, & Neville Bittar. (1990). A multicenter dose response study of sustained release diltiazem hydrochloride in angina pectoris. Journal of the American College of Cardiology. 15(2). A172–A172. 3 indexed citations
10.
Awan, Najam A. & Dean T. Mason. (1982). Vasodilator therapy of severe congestive heart failure: The special importance of angiotensin-converting enzyme inhibition with captopril. American Heart Journal. 104(5). 1127–1136. 15 indexed citations
11.
Awan, Najam A., et al.. (1981). Therapeutic application of prazosin in chronic refractory congestive heart failure. The American Journal of Medicine. 71(1). 153–160. 21 indexed citations
12.
Awan, Najam A., et al.. (1981). Efficacy of oral angiotensin-converting enzyme inhibition with captopril therapy in severe chronic normotensive congestive heart failure. American Heart Journal. 101(1). 22–31. 90 indexed citations
13.
Laslett, Lawrence, Ezra A. Amsterdam, & Najam A. Awan. (1979). Prolonged afterload reduction and cardiac output augmentation by oral prazosin in acute myocardial infarction with congestive heart failure. Clinical research. 27(1). 1 indexed citations
14.
Awan, Najam A., et al.. (1979). Comparison of oral trimazosin with nitroprusside: Equal balanced afterload reduction in vasodilator treatment of severe congestive heart failure. Clinical research. 27(1). 1 indexed citations
15.
Amsterdam, Ezra A., Najam A. Awan, Anthony N. DeMaria, et al.. (1979). Sustained salutary effects of oral controlled‐release nitroglycerin on ventricular function in congestive heart failure. Clinical Cardiology. 2(1). 19–25. 5 indexed citations
17.
Miller, Richard R., Najam A. Awan, Anthony N. DeMaria, Ezra A. Amsterdam, & Dean T. Mason. (1977). Importance of maintaining systemic blood pressure during nitroglycerin administration for reducing ischemic injury in patients with coronary disease. The American Journal of Cardiology. 40(4). 504–508. 41 indexed citations
18.
Awan, Najam A., Louis A. Vismara, Richard R. Miller, Anthony N. DeMaria, & D. T. Mason. (1977). Effects of isometric exercise and increased arterial impedance on left ventricular function in severe aortic valvular stenosis.. Heart. 39(6). 651–656. 9 indexed citations
19.
Awan, Najam A., Ezra A. Amsterdam, Zakauddin Vera, & D. T. Mason. (1975). Clinical effects of nitroglycerin on extent of ischemic injury in acute myocardial infarction assessed by precordial ST segment mapping. Circulation. 52. 1 indexed citations
20.
Vera, Zakauddin, Najam A. Awan, Ezra A. Amsterdam, & D. T. Mason. (1975). Cardiac pacemakers: indications and complications.. PubMed. 4(3). 444–51. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026